PH-Icatibant: payments to doctors
Payments that named PH-Icatibant as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $65K
- Providers
- 10
- Transactions
- 48
- Average per transaction
- $1,349
The per-transaction average — $1,349 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 10 providers the average total is $6,477, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Fresenius Kabi USA, LLC | $64,767 | 100.0% |